<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Almanac of Clinical Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Almanac of Clinical Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Альманах клинической медицины</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-0505</issn><issn publication-format="electronic">2587-9294</issn><publisher><publisher-name xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17224</article-id><article-id pub-id-type="doi">10.18786/2072-0505-2024-52-004</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Association between full blood count and urine steroid metabolome in patients with adrenal masses</article-title><trans-title-group xml:lang="ru"><trans-title>Взаимосвязь показателей клинического анализа крови и стероидного метаболома мочи у больных с объемными образованиями надпочечников</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9574-105X</contrib-id><name-alternatives><name xml:lang="en"><surname>Vorokhobina</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Ворохобина</surname><given-names>Наталья Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Head of Chair of Endocrinology named after academician V.G. Baranov</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующая кафедрой эндокринологии им. акад. В.Г. Баранова</p></bio><email>natvorokh@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2812-6911</contrib-id><name-alternatives><name xml:lang="en"><surname>Kalugina</surname><given-names>Valentina V.</given-names></name><name xml:lang="ru"><surname>Калугина</surname><given-names>Валентина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate Student, Chair of Endocrinology named after academician V.G. Baranov</p></bio><bio xml:lang="ru"><p>аспирант кафедры эндокринологии им. акад. В.Г. Баранова</p></bio><email>kaluginavav@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9352-4035</contrib-id><name-alternatives><name xml:lang="en"><surname>Velikanova</surname><given-names>Ludmila I.</given-names></name><name xml:lang="ru"><surname>Великанова</surname><given-names>Людмила Иосифовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Doctor of Biol. Sci., Professor, Head of Science and Research Laboratory of Chromatography</p></bio><bio xml:lang="ru"><p>д-р биол. наук, профессор, заведующая научно-исследовательской лабораторией хроматографии</p></bio><email>velikanova46@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8292-8504</contrib-id><name-alternatives><name xml:lang="en"><surname>Shafigullina</surname><given-names>Zulfiya R.</given-names></name><name xml:lang="ru"><surname>Шафигуллина</surname><given-names>Зульфия Ривгатовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Associate Professor, Chair of Endocrinology named after academician V.G. Baranov</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент кафедры эндокринологии им. акад. В.Г. Баранова</p></bio><email>zula183@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0880-0814</contrib-id><name-alternatives><name xml:lang="en"><surname>Malevanaya</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Малеваная</surname><given-names>Екатерина Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (in Chem.), Senior Research Fellow, Science and Research Laboratory of Chromatography</p></bio><bio xml:lang="ru"><p>канд. хим. наук, ст. науч. сотр. научно-исследовательской лаборатории хроматографии</p></bio><email>e.malevanaia@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2045-0044</contrib-id><name-alternatives><name xml:lang="en"><surname>Lisitsyn</surname><given-names>Aleksandr A.</given-names></name><name xml:lang="ru"><surname>Лисицын</surname><given-names>Александр Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Associate Professor, Chair of Faculty Surgery named after I.I. Grekov</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент кафедры факультетской хирургии им. И.И. Грекова</p></bio><email>9213244516@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">North-Western State Medical University named after I.I. Mechnikov</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-04-09" publication-format="electronic"><day>09</day><month>04</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-09-10" publication-format="electronic"><day>10</day><month>09</month><year>2024</year></pub-date><volume>52</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>140</fpage><lpage>148</lpage><history><date date-type="received" iso-8601-date="2024-02-12"><day>12</day><month>02</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-03-29"><day>29</day><month>03</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Vorokhobina N.V., Kalugina V.V., Velikanova L.I., Shafigullina Z.R., Malevanaya E.V., Lisitsyn A.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Ворохобина Н.В., Калугина В.В., Великанова Л.И., Шафигуллина З.Р., Малеваная Е.В., Лисицын А.А.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Vorokhobina N.V., Kalugina V.V., Velikanova L.I., Shafigullina Z.R., Malevanaya E.V., Lisitsyn A.A.</copyright-holder><copyright-holder xml:lang="ru">Ворохобина Н.В., Калугина В.В., Великанова Л.И., Шафигуллина З.Р., Малеваная Е.В., Лисицын А.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://almclinmed.ru/jour/article/view/17224">https://almclinmed.ru/jour/article/view/17224</self-uri><abstract xml:lang="en"><p><bold>Background</bold>: Endogenous hypercortisolism of adrenal origin is commonly associated with immune suppression. However, these patients also have signs characteristic of chronic inflammatory diseases. Better understanding of the mechanisms that alter the functioning of the immune system would allow for the development of a patient-centered approach to the treatment of corticotropin-independent endogenous Cushing's syndrome (CS).</p> <p><bold>Aim</bold>: To assess the association between full blood count and gas chromatography-mass spectrometry-based urinary steroid excretion in patients with adrenal masses depending on malignancy grade and presence of hypercortisolism.</p> <p><bold>Materials and methods</bold>: We retrospectively analyzed data from 42 patients with adrenal masses who had not received chemotherapy. The median age of the patients was 54 [Q25; Q75: 37; 63] years, and 76% of them were female. Preoperatively, all patients had hematology tests with differential leukocyte count. Steroid metabolome was assessed with Shimadzu GCMS-TQ8050 gas chromatography-mass spectrometer.</p> <p><bold>Results</bold>: Twelve (12) patients had adrenocortical cancer (ACC) and CS, 9 patients had ACC without CS, 11 had adrenocortical adenomas (ACA) and CS, and 10 patients had ACA without CS. ACC patients had a higher neutrophil-to-lymphocyte ratio (NLR) than those with ACA: 3.35 [2.5; 6.3] vs 1.99 [1.41; 2.65] (р = 0.001). There was a linear correlation between NLR and serum cortisol levels after the 1 mg overnight dexamethasone suppression test (r = 0.41, p = 0.01), urinary excretion of 5β-tetrahydrocortisol (5β-THF) (r = 0.71, p &lt; 0.001) and 11β-hydroxyandrosterone (11β-OH-An) (r = 0.74, p &lt; 0.001). The ACC patients without CS had lower 5β-THF urinary excretion values, compared to ACA with CS patients: 931 [616; 1610] and 3139 [1480; 4375] mcg/24h, respectively (р = 0.007). 11β-OH-An urinary excretion in ACC patients without CS was higher than in ACA patients with CS: 1170 [806; 1266] и 602 [320; 739] mcg/24h (р = 0.007). The NLR cut-off value for adrenal mass malignancy in patients with CS exceeded 2.72 (sensitivity 90.0%, specificity 80.0%), and for the patients without hypercortisolism was above 1.92 (sensitivity 71.4%, specificity 100.0%).</p> <p><bold>Conclusion</bold>: This is the first association identification between NLR, which is the marker of systemic inflammation, inflammation, and urinary excretion of 11β-OH-An, a metabolite of 11-hydroxyandrostenedione (a member of 11-oxygenated androgen family). This extends our understanding of the impact of hormonal activity of adrenal mass cells on the immune system.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование</bold>. Традиционно эндогенный гиперкортизолизм ассоциируется с иммунной супрессией, однако у таких больных наблюдаются и признаки, свойственные хроническим воспалительным заболеваниям. Лучшее понимание механизмов, изменяющих функционирование иммунной системы, позволит разработать пациент-ориентированный подход к лечению больных кортикотропин-независимым эндогенным синдромом Кушинга (СК).</p> <p><bold>Цель</bold> – установить связь показателей периферической крови больных с объемными образованиями надпочечников и экскреции кортикостероидов с мочой, исследованной методом газовой хромато-масс-спектрометрии, в зависимости от злокачественности опухоли и наличия гиперкортизолизма.</p> <p><bold>Материал и методы</bold>. Ретроспективно проанализированы данные обследования 42 больных с новообразованиями надпочечников, не получавших химиотерапевтического лечения в анамнезе. Медиана возраста обследованных составила 54 [Q25; Q75: 37; 63] года, женщин было 76% (32/42). В дооперационном периоде всем пациентам выполнен клинический анализ крови с определением лейкоцитарной формулы, исследован стероидный метаболом мочи на газовом хромато-масс-спектрометре Shimadzu GCMS-ТQ8050.</p> <p><bold>Результаты</bold>. У 12 пациентов был адренокортикальный рак (АКР) и СК, у 9 – АКР без СК, у 11 – адренокортикальные аденомы (АКА) и СК, у 10 – АКА без СК. Определено большее значение нейтрофильно-лимфоцитарного индекса (НЛИ) у больных АКР по сравнению с больными АКА: 3,35 [2,5; 6,3] и 1,99 [1,41; 2,65] (р = 0,001). Выявлена линейная зависимость НЛИ от уровня кортизола крови после ночного подавляющего теста с 1 мг дексаметазона (r = 0,41, p = 0,01), экскреции с мочой 5β-тетрагидрокортизола (r = 0,71, p &lt; 0,001) и 11β-гидроксиандростерона (r = 0,74, p &lt; 0,001). Установлены меньшие значения экскреции 5β-тетрагидрокортизола у больных АКР без СК по сравнению с больными АКА с СК: 931 [616; 1610] и 3139 [1480; 4375] мкг/сут (р = 0,007). Экскреция с мочой 11β-гидроксиандростерона у больных АКР без СК была выше в отличие от больных АКА с СК: 1170 [806; 1266] и 602 [320; 739] мкг/сут (р = 0,007). Пороговое значение НЛИ для определения злокачественного потенциала опухоли надпочечника у больных с СК составило более 2,72 (чувствительность – 90,0%, специфичность – 80,0%), для пациентов без гиперкортизолизма – более 1,92 (чувствительность – 71,4%, специфичность – 100,0%).</p> <p><bold>Заключение</bold>. Впервые получены данные о зависимости НЛИ, отражающего уровень системного воспаления, от экскреции с мочой 11β-гидроксиандростерона, метаболита 11-гидроксиандростендиона, представителя 11-оксигенированных андрогенов, что расширяет представления о воздействии на иммунную систему гормональной активности клеток опухолей надпочечников.</p></trans-abstract><kwd-group xml:lang="en"><kwd>adrenocortical cancer</kwd><kwd>Cushing's syndrome</kwd><kwd>urine steroid metabolome</kwd><kwd>gas chromatography-mass spectrometry</kwd><kwd>neutrophil-to-lymphocyte ratio</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>адренокортикальный рак</kwd><kwd>синдром Кушинга</kwd><kwd>стероидный метаболом мочи</kwd><kwd>газовая хромато-масс-спектрометрия</kwd><kwd>нейтрофильно-лимфоцитарный индекс</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Министерство здравоохранения Российской Федерации</institution></institution-wrap><institution-wrap><institution xml:lang="en">Ministry of Health of the Russian Federation</institution></institution-wrap></funding-source><award-id>122012100080-3</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Prete A, Subramanian A, Bancos I, Chortis V, Tsagarakis S, Lang K, Macech M, Delivanis DA, Pupovac ID, Reimondo G, Marina LV, Deutschbein T, Balomenaki M, O'Reilly MW, Gilligan LC, Jenkinson C, Bednarczuk T, Zhang CD, Dusek T, Diamantopoulos A, Asia M, Kondracka A, Li D, Masjkur JR, Quinkler M, Ueland GÅ, Dennedy MC, Beuschlein F, Tabarin A, Fassnacht M, Ivović M, Terzolo M, Kastelan D, Young WF Jr, Manolopoulos KN, Ambroziak U, Vassiliadi DA, Taylor AE, Sitch AJ, Nirantharakumar K, Arlt W; ENSAT EURINE-ACT Investigators*; ENSAT EURINE-ACT Investigators. Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study. Ann Intern Med. 2022;175(3):325–334. doi: 10.7326/M21-1737.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009;161(4):513–527. doi: 10.1530/EJE-09-0234.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Hasenmajer V, Sbardella E, Sciarra F, Minnetti M, Isidori AM, Venneri MA. The Immune System in Cushing's Syndrome. Trends Endocrinol Metab. 2020;31(9):655–669. doi: 10.1016/j.tem.2020.04.004.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Favero V, Prete A, Mangone A, Elhassan YS, Pucino V, Asia M, Hardy R, Chiodini I, Ronchi CL. Inflammation-based scores in benign adrenocortical tumours are linked to the degree of cortisol excess: a retrospective single-centre study. Eur J Endocrinol. 2023;189(5):517–526. doi: 10.1093/ejendo/lvad151.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Marques P, de Vries F, Dekkers OM, van Furth WR, Korbonits M, Biermasz NR, Pereira AM. Pre-operative serum inflammation-based scores in patients with pituitary adenomas. Pituitary. 2021;24(3):334–350. doi: 10.1007/s11102-020-01112-5.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Sisman P, Bicer B, Gul OO, Cander S, Ersoy C, Saraydaroglu O, Erturk E. May hemocytometer parameters be a biomarker in distinguishing between adrenal adenomas and carcinomas and in prognosis of adrenocortical carcinomas? Acta Clin Croat. 2020;59(3):439–444. doi: 10.20471/acc.2020.59.03.07.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Detomas M, Altieri B, Chifu I, Remde H, Zhou X, Landwehr LS, Sbiera S, Kroiss M, Fassnacht M, Deutschbein T. Subtype-specific pattern of white blood cell differential in endogenous hypercortisolism. Eur J Endocrinol. 2022;187(3):439–449. doi: 10.1530/EJE-22-0211.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Paja M, Merlo I, Rodríguez-Soto J, Cruz-Iglesias E, Moure MD, Elías C, Oleaga A, Egaña N. White blood cell count: a valuable tool for suspecting Cushing's syndrome. J Endocrinol Invest. 2023;46(1):141–149. doi: 10.1007/s40618-022-01892-6.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Wang W, Wang J, Shen C, Zhu S, Gao Y, Zhang J. Neutrophil-Lymphocyte Ratio as an Initial Screening Biomarker for Differential Diagnosis of Cushing's Syndrome from Nonfunctional Adenoma in Patients with an Adrenal Mass. Biomed Res Int. 2021;2021:6635594. doi: 10.1155/2021/6635594.</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Velikanova LI, Vorokhobina NV, Shafigullina ZR, Kalugina VV, Malevanaya EV, Strelnikova EG, Buinova MO, Lisitsyn AA, Kushlinskii NE. [The relationship between urine steroid metabolome and the course of adrenocortical cancer]. Almanac of Clinical Medicine. 2023;51(3):143–153. Russian. doi: 10.18786/2072-0505-2023-51-018.</mixed-citation><mixed-citation xml:lang="ru">Великанова ЛИ, Ворохобина НВ, Шафигуллина ЗР, Калугина ВВ, Малеваная ЕВ, Стрельникова ЕГ, Буйнова МО, Лисицын АА, Кушлинский НЕ. Взаимосвязь стероидного метаболома мочи с течением адренокортикального рака. Альманах клинической медицины. 2023;51(3):143–153. doi: 10.18786/2072-0505-2023-51-018.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><mixed-citation>Velikanova LI, Shafigullina ZR, Lisitsin AA, Vorokhobina NV, Grigoryan K, Kukhianidze EA, Strelnikova EG, Krivokhizhina NS, Krasnov LM, Fedorov EA, Sablin IV, Moskvin AL, Bessonova EA. Different Types of Urinary Steroid Profiling Obtained by High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectrometry in Patients with Adrenocortical Carcinoma. Horm Cancer. 2016;7(5–6):327–335. doi: 10.1007/s12672-016-0267-0.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, Porfiri E, Opocher G, Bertherat J, Mantero F, Allolio B, Terzolo M, Nightingale P, Shackleton CH, Bertagna X, Fassnacht M, Stewart PM. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011;96(12):3775–3784. doi: 10.1210/jc.2011-1565.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chortis V, Bancos I, Nijman T, Gilligan LC, Taylor AE, Ronchi CL, O'Reilly MW, Schreiner J, Asia M, Riester A, Perotti P, Libé R, Quinkler M, Canu L, Paiva I, Bugalho MJ, Kastelan D, Dennedy MC, Sherlock M, Ambroziak U, Vassiliadi D, Bertherat J, Beuschlein F, Fassnacht M, Deeks JJ, Biehl M, Arlt W. Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2020;105(3):e307–e318. doi: 10.1210/clinem/dgz141.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B; German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115(2):243–250. doi: 10.1002/cncr.24030.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8(3):163–169. doi: 10.1097/00000478-198403000-00001.</mixed-citation></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Velikanova LI, Strel'nikova EG, Obedkova EV, Krivokhizhina NS, Shafigullina ZR, Grigoryan K, Povarov VG, Moskvin AL. Generation of urinary steroid profiles in patients with adrenal incidentaloma using gas chromatography-mass spectrometry. J Anal Chem. 2016;71(7):748–754. doi: 10.1134/S1061934816070169.</mixed-citation><mixed-citation xml:lang="ru">Великанова ЛИ, Стрельникова ЕГ, Объедкова ЕВ, Кривохижина НС, Шафигуллина ЗР, Григорян К, Поваров ВГ, Москвин АЛ. Получение стероидных профилей мочи больных с инциденталомой надпочечников методом газовой хромато-масс-спектрометрии. Журнал аналитической химии. 2016;71(7):775–781. doi: 10.7868/S0044450216070161.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>Shackleton CH, Neres MS, Hughes BA, Stewart PM, Kater CE. 17-Hydroxylase/C17,20-lyase (CYP17) is not the enzyme responsible for side-chain cleavage of cortisol and its metabolites. Steroids. 2008;73(6):652–656. doi: 10.1016/j.steroids.2008.02.001.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Schiffer L, Barnard L, Baranowski ES, Gilligan LC, Taylor AE, Arlt W, Shackleton CHL, Storbeck KH. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review. J Steroid Biochem Mol Biol. 2019;194:105439. doi: 10.1016/j.jsbmb.2019.105439.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Chakraborty S, Pramanik J, Mahata B. Revisiting steroidogenesis and its role in immune regulation with the advanced tools and technologies. Genes Immun. 2021;22(3):125–140. doi: 10.1038/s41435-021-00139-3.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kroon J, Pereira AM, Meijer OC. Glucocorticoid Sexual Dimorphism in Metabolism: Dissecting the Role of Sex Hormones. Trends Endocrinol Metab. 2020;31(5):357–367. doi: 10.1016/j.tem.2020.01.010.</mixed-citation></ref></ref-list></back></article>
